Is It Time To Reassess Cencora (COR) After The Recent Share Price Pullback

Simply Wall St.03-21

Investors may be wondering whether Cencora's share price still offers value after a strong run, or if most of the upside is already in the rear-view mirror. The stock last closed at US$326.91, with a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621479396?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/24809-main-header/1756252652273","is_english":true,"pubTime":"2026-03-21 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621479396","market":"nz","top_or_hot":-1,"title":"Is It Time To Reassess Cencora (COR) After The Recent Share Price Pullback","media":"Simply Wall St.","content":"<div>\n<p>Investors may be wondering whether Cencora's share price still offers value after a strong run, or if most of the upside is already in the rear-view mirror. The stock last closed at US$326.91, with a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/is-it-time-to-reassess-cencora-cor-after-the-recent-share-pr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess Cencora (COR) After The Recent Share Price Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess Cencora (COR) After The Recent Share Price Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-21 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/is-it-time-to-reassess-cencora-cor-after-the-recent-share-pr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors may be wondering whether Cencora's share price still offers value after a strong run, or if most of the upside is already in the rear-view mirror. The stock last closed at US$326.91, with a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/is-it-time-to-reassess-cencora-cor-after-the-recent-share-pr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237957811.SGD","symbol_name":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/is-it-time-to-reassess-cencora-cor-after-the-recent-share-pr","article_id":"2621479396","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/24809-main-header/1756252652273"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/is-it-time-to-reassess-cencora-cor-after-the-recent-share-pr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621479396","pubTimestamp":1774105667,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Investors may be wondering whether Cencora's share price still offers value after a strong run, or if most of the upside is already in the rear-view mirror.\nThe stock last closed at US$326.91, with a 7 day return of a 6.6% decline and a 30 day return of a 9.2% decline, while the 1 year return stands at 23.1% and the 3 year and 5 year returns are 114.6% and 190.3% respectively.\nRecent news around Cencora has focused on its role as a major healthcare distributor and how investors interpret...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","COR":"CENCORA","BK4588":"碎股","LU1261432733.SGD":"Fidelity World A-ACC-SGD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4084":"特种房地产投资信托","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","BK4529":"IDC概念","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK4175":"保健护理产品经销商","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"近期股价回调后，是时候重新评估Cencora(COR)了吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COR":1.5,"DCF":1},"content_text":"Investors may be wondering whether Cencora's share price still offers value after a strong run, or if most of the upside is already in the rear-view mirror. The stock last closed at US$326.91, with a 7 day return of a 6.6% decline and a 30 day return of a 9.2% decline, while the 1 year return stands at 23.1% and the 3 year and 5 year returns are 114.6% and 190.3% respectively. Recent news around Cencora has focused on its role as a major healthcare distributor and how investors interpret that position in the current market context. This backdrop helps explain why the share price has seen both strong multi year returns and shorter term pullbacks. Cencora currently holds a valuation score of 3 out of 6. The next sections will unpack what different valuation methods say about the stock and will point to a more complete way to think about value at the very end of the article.  Cencora delivered 23.1% returns over the last year. See how this stacks up to the rest of the Healthcare industry. AdvertisementApproach 1: Cencora Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model looks at the cash Cencora is expected to generate in the future and discounts those projected cash flows back to today to estimate what the business might be worth now. Cencora’s latest reported Free Cash Flow is about $3.69b. Analyst and extrapolated projections used in this 2 Stage Free Cash Flow to Equity model estimate annual Free Cash Flow between roughly $3.0b and $5.8b over the coming years, with a projected figure of $4.84b in 2030. Simply Wall St uses analyst estimates where available and then extends the series using its own growth assumptions to complete a ten year cash flow path. After discounting these projected cash flows back to today, the DCF model estimates an intrinsic value of about $601.42 per share, compared with the recent share price of $326.91. This implies an intrinsic discount of 45.6%, which indicates that Cencora may be trading at a substantial markdown relative to this cash flow based estimate of value. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 45.6%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks. COR Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Cencora. Approach 2: Cencora Price vs Earnings For a profitable company, the P/E ratio is a straightforward way to relate what you are paying per share to the earnings that support that price. It gives a quick sense of how many dollars investors are currently willing to pay for each dollar of earnings. What counts as a “normal” P/E usually reflects how investors view a company’s growth prospects and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher uncertainty tends to align with a lower multiple. Cencora currently trades on a P/E of 39.13x. This sits above the Healthcare industry average of 21.22x and also above the peer group average of 21.66x. Simply Wall St’s Fair Ratio for Cencora is 37.09x, which is its proprietary estimate of what a balanced P/E might look like after considering factors such as earnings growth, profit margins, industry, market cap and risk profile. The Fair Ratio can be more informative than a simple comparison to peers or the broad industry, because it adjusts for Cencora specific characteristics rather than assuming all companies should trade on the same multiple. With the current P/E slightly above the Fair Ratio, the stock screens as modestly overvalued on this metric. Result: OVERVALUED NYSE:COR P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your Cencora Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are a simple way for you to attach a clear story about Cencora to the numbers you care about, linking your view of its future revenue, earnings and margins to a forecast and then to a fair value, all within an easy tool on Simply Wall St's Community page that updates as news or earnings arrive and helps you compare your Fair Value with the current share price when thinking about buying or selling, whether you lean closer to an optimistic view that aligns with a US$355 price target or a more cautious stance nearer US$274. Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying! NYSE:COR 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621479396","isCrawlerRequest":true}